Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors.
Domingo E. et al, (2024), EBioMedicine, 106
Validation of High-Performance Low-Field-Strength T1-weighted neuroimaging sequence modelling
WHYNTIE TOM. et al, (2021)
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
Sirinukunwattana K. et al, (2021), Gut, 70, 544 - 554
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Malla SB. et al, (2021), Clin Cancer Res, 27, 288 - 300
A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment.
Viratham Pulsawatdi A. et al, (2020), Mol Oncol, 14, 2384 - 2402
Fusobacterium nucleatum, rectal cancer and radiotherapy.
Mann EH. and Maughan TS., (2020), Ann Oncol
Exploration of molecular signalling underpinning the DNA Damage Response Deficiency (DDRD) assay in Colorectal Cancer; Data from the S:CORT consortium (Stratification in COlorRecTal cancer)
Malla S. et al, (2019), BRITISH JOURNAL OF CANCER, 121, 3 - 3
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Gray V. et al, (2019), J Natl Cancer Inst, 111, 828 - 836
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Schiavone F. et al, (2019), Trials, 20
Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.
Henderson R. et al, (2019), Oncotarget, 10, 3408 - 3423
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Law PJ. et al, (2019), Nat Commun, 10
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
McGowan DR. et al, (2019), Eur J Cancer, 113, 87 - 95
Guidelines for using sigQC for systematic evaluation of gene signatures.
Dhawan A. et al, (2019), Nat Protoc, 14, 1377 - 1400
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141